{
  "success": true,
  "pagesUsed": [
    0,
    1,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    20,
    21,
    22,
    23,
    24,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Upadacitinib",
        "type": {
          "id": "e2743140-71f4-414e-a5d4-75c924271681",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "dc6ba0b5-37de-4b4e-aa44-21cd6cfbdf2b",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Methotrexate (MTX)",
        "type": {
          "id": "c63d8e84-e0b0-4f0c-8fe2-9f8b3d4b46a0",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "role": {
          "id": "8923da10-4ce6-42fc-873f-fe7aa3a05aae",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Active comparator for Period 1; background therapy or discontinued in Period 2.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Placebo for Upadacitinib",
        "type": {
          "id": "b7e0af16-085d-496d-8b96-3af84ea9fb73",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "0adf1ac9-2244-4909-892a-bae07009ac3a",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo tablet for upadacitinib to maintain blinding.",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Placebo for MTX",
        "type": {
          "id": "4276264c-a43f-47d8-b033-55afdbb70fd1",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "e371a291-3fb7-46cf-872c-f7560e3f03ae",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo capsules for methotrexate to maintain blinding.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Folic acid",
        "type": {
          "id": "259e5e84-b1fe-4abc-9c1a-7cf5f571538d",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "405fdb93-95e0-4f8b-8ecd-fcaf147f3467",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Required dietary supplement for subjects taking MTX."
      },
      {
        "id": "int_6",
        "name": "Corticosteroids",
        "type": {
          "id": "c8602f70-49b3-4191-ad9e-70c38db2eafe",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "74fb2025-e9e9-4b2e-a18d-799c06441db3",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral corticosteroids (≤ 10 mg/day prednisone equivalent) permitted if stable; rescue use allowed after Week 26."
      },
      {
        "id": "int_7",
        "name": "NSAIDs",
        "type": {
          "id": "64aa86bd-9f1b-49ab-9196-7d305f3d6117",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "18c9ad3c-dbc3-40be-be98-9476dc9289f6",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted if dose is stable for at least 1 week prior to first dose."
      },
      {
        "id": "int_8",
        "name": "Acetaminophen",
        "type": {
          "id": "7eeb97fb-116f-4382-aa81-bdd325119b18",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "4e680d98-7cf8-43d7-a92a-f2f483b82e12",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted for pain management."
      },
      {
        "id": "int_9",
        "name": "csDMARDs",
        "type": {
          "id": "6c25065c-9a0c-4fc5-b484-7014d77a9b50",
          "code": "C54125",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Rescue Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "9230bcde-a6ec-4640-9498-feeb91aba991",
          "code": "C54125",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Rescue Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Initiation or adjustment allowed starting at Week 26 for subjects not achieving LDA."
      },
      {
        "id": "int_10",
        "name": "Strong CYP3A inhibitors/inducers",
        "type": {
          "id": "cabe754f-8d30-45f6-afb3-df368fdab26d",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "332c8eaa-7b56-473f-acca-922821e4994e",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited from Screening through the end of the study."
      },
      {
        "id": "int_11",
        "name": "High-potency opiates",
        "type": {
          "id": "113a2cfb-62ea-4682-8660-6ef99231fae0",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "8cd24c6c-87bb-4fe1-a664-8a3e2d50ba7c",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited during the study; must be washed out 1 week prior to first dose."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Upadacitinib tablet",
        "administrableDoseForm": {
          "id": "102cf242-efeb-4d0b-81e8-4488dc1c9333",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "952a534a-cfac-45a4-9f2e-5c3308bb6881",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "34efc741-dd1e-4c44-b2d9-86f8ff322ceb",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "15 mg, 30 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "AbbVie"
      },
      {
        "id": "prod_2",
        "name": "Methotrexate capsule",
        "administrableDoseForm": {
          "id": "daf820df-0370-4b53-878f-1fa42f2fd053",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "1876d469-e3ac-48df-947a-d1872deefa00",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "ef50faed-6ba1-4719-9771-7778259e642e",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "7.5 mg, 10 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Not specified"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Upadacitinib 15 mg QD",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Up to 260 weeks"
      },
      {
        "id": "admin_2",
        "name": "Upadacitinib 30 mg QD",
        "instanceType": "Administration",
        "dose": "30 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Period 1 and Period 2 (until Amendment 5)"
      },
      {
        "id": "admin_3",
        "name": "Methotrexate weekly",
        "instanceType": "Administration",
        "dose": "7.5 mg to 25 mg",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "14 weeks (Period 1)"
      },
      {
        "id": "admin_4",
        "name": "Upadacitinib 15 mg Open-Label",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Starting with Amendment 5 for all subjects"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Upadacitinib",
        "instanceType": "Substance",
        "description": "Selective Janus kinase 1 (JAK1) inhibitor; substance code ABT-494."
      },
      {
        "id": "sub_2",
        "name": "Methotrexate",
        "instanceType": "Substance",
        "description": "Antifolate antineoplastic and antirheumatic drug."
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 11,
      "productCount": 2,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Upadacitinib",
        "role": "Investigational Product",
        "description": "Selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis."
      },
      {
        "name": "Methotrexate (MTX)",
        "role": "Comparator",
        "description": "Active comparator for Period 1; background therapy or discontinued in Period 2."
      },
      {
        "name": "Placebo for Upadacitinib",
        "role": "Placebo",
        "description": "Matching placebo tablet for upadacitinib to maintain blinding."
      },
      {
        "name": "Placebo for MTX",
        "role": "Placebo",
        "description": "Matching placebo capsules for methotrexate to maintain blinding."
      },
      {
        "name": "Folic acid",
        "role": "Background Therapy",
        "description": "Required dietary supplement for subjects taking MTX."
      },
      {
        "name": "Corticosteroids",
        "role": "Concomitant Medication",
        "description": "Oral corticosteroids (≤ 10 mg/day prednisone equivalent) permitted if stable; rescue use allowed after Week 26."
      },
      {
        "name": "NSAIDs",
        "role": "Concomitant Medication",
        "description": "Permitted if dose is stable for at least 1 week prior to first dose."
      },
      {
        "name": "Acetaminophen",
        "role": "Concomitant Medication",
        "description": "Permitted for pain management."
      },
      {
        "name": "csDMARDs",
        "role": "Rescue Medication",
        "description": "Initiation or adjustment allowed starting at Week 26 for subjects not achieving LDA."
      },
      {
        "name": "Strong CYP3A inhibitors/inducers",
        "role": "Concomitant Medication",
        "description": "Prohibited from Screening through the end of the study."
      },
      {
        "name": "High-potency opiates",
        "role": "Concomitant Medication",
        "description": "Prohibited during the study; must be washed out 1 week prior to first dose."
      }
    ],
    "products": [
      {
        "name": "Upadacitinib tablet",
        "doseForm": "Tablet",
        "strength": "15 mg, 30 mg",
        "manufacturer": "AbbVie"
      },
      {
        "name": "Methotrexate capsule",
        "doseForm": "Capsule",
        "strength": "7.5 mg, 10 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg",
        "manufacturer": "Not specified"
      }
    ],
    "substances": [
      {
        "name": "Upadacitinib",
        "description": "Selective Janus kinase 1 (JAK1) inhibitor; substance code ABT-494."
      },
      {
        "name": "Methotrexate",
        "description": "Antifolate antineoplastic and antirheumatic drug."
      }
    ],
    "administrations": [
      {
        "name": "Upadacitinib 15 mg QD",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Up to 260 weeks"
      },
      {
        "name": "Upadacitinib 30 mg QD",
        "dose": "30 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Period 1 and Period 2 (until Amendment 5)"
      },
      {
        "name": "Methotrexate weekly",
        "dose": "7.5 mg to 25 mg",
        "frequency": "once weekly",
        "route": "Oral",
        "duration": "14 weeks (Period 1)"
      },
      {
        "name": "Upadacitinib 15 mg Open-Label",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Starting with Amendment 5 for all subjects"
      }
    ],
    "devices": []
  }
}